4 active not recruiting, 2 completed. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 3, Completed 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Refractory Glioma: new trials by email Literature Review of Refractory Glioma trials Research Report on Refractory Glioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma HER2(EQ)BBζ/CD19t+ T cells, Laboratory Biomarker Analysis, Leukapheresis - Glioblastoma, Malignant Glioma | Phase 1 | Active not recruiting | City of Hope Medical Center | 29 | 2018-08-14 | 2026-02-04 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-06-17 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
Glioma (6) · Ependymoma (5) · Hepatoblastoma (5) · Histiocytosis, Langerhans-Cell (5) · Lymphoma, Non-Hodgkin (5) · Medulloblastoma (5) · Neuroblastoma (5) · Neuroectodermal Tumors, Primitive, Peripheral (5) · Osteosarcoma (5) · Rhabdoid Tumor (5) · Rhabdomyosarcoma (5) · Sarcoma (5) · Wilms Tumor (5) · Central Nervous System Neoplasms (3) · Sarcoma, Ewing (3)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Nerve Tissue (6) · Neoplasms, Neuroepithelial (6) · Neuroectodermal Tumors (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genetic Diseases, Inborn (5) · Hemic and Lymphatic Diseases (5) · Histiocytosis (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5)
Biopsy (2) · Magnetic Resonance Spectroscopy (2) · Nuclear Medicine Department, Hospital (2) · Phantoms, Imaging (2) · Specimen Handling (2) · X-Rays (2) · larotrectinib (2) · olaparib (2) · palbociclib (2) · ulixertinib (2) · LY3023414 (1) · Leukapheresis (1) · Pharmacogenomic Variants (1) · Vemurafenib (1) · ensartinib (1)
National Cancer Institute (NCI) (5) · City of Hope Medical Center (1)
United States (6) · Puerto Rico (5) · Australia (1) · Canada (1)
Behnam Badie (1) · Donald W Parsons (1) · Julia Glade-Bender (1) · Katherine A Janeway (1) · Kieuhoa T Vo (1) · Rajen Mody (1)
PMID 31401903, PMID 33591402, PMID 35353553, PMID 38815151, PMID 38935895, PMID 39298716, PMID 41166674, PMID 42686334
U10CA180886 (5), P30CA033572 (1)